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ANIMAL MODELS AND GENE THERAPY FOR DIABETIC NEUROPATHY
Classification Model Characteristics Advantages Disadvantages
Chemically
induced 
models
Drug:  STZ
Drug: Alloxan
Necrosis of pancreatic β-cells by:
Alkylation of DNA  and production of ROS  
Destruction of pancreatic β-cells by:
Superoxide radicals and massive increase of cytosolic 
calcium concentration
Easy administration, cheap and  good experimental 
protocols for many species
Easy administration and cheap
Toxicity in other parts of the body: renal failure and endothelial 
inflammation/dysfunction
Without autoimmunity
Range of diabetogenic dose is quite narrow
High loss of animal from kidney tubular cell necrotic toxicity
Without autoimmunity
Surgical models Pancreatectomy Partial or complete removal of the pancreasFirst model used in investigation − Expensive, high loss of animals and not autoimmunity
NOD mouse
Diabetes: 24-30 weeks
Autoantibodies: insulin, GAD and IA-2
Hiperglycaemia, glycosuria, polydipsia, polyuria, thyroiditis
and Sjögren’s syndrome
Autoantibodies and clinical signs equal to humans
Animal model to study autoimmunity in diabetes Insulitis has many differences from human insulitisResistance to ketoacidosis
Introduction: Diabetic Neuropathy
• Neural dysfunction characterized for lower nerve signal conduction speed, axonal degeneration and strange regeneration of
axons. This neuropathy leads to different abnormalities like numbness, tingling, burning, and shooting pain in the legs and
reduced pain, touch, and vibratory perception in a symmetrical stocking glove distribution
• Most common complication in diabetes, appears in more than 50% of patients
• It develops because the hyperglycemia but its specific pathways are still in study (Figure 1)
• No available treatment for diabetic neuropathy other than glycemic control and diligent foot care
• For these reasons:
1. It is important to have animal models for diabetes to study its complications
2. It is necessary develops new therapies for diabetic neuropathy
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Figure 1. Diagram of hyperglycemic effects on biochemical pathways in diabetic neuropathy. Modified
from Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: the oxidative stress theory
of diabetic neuropathy Rev Endocr Metab Disord 2008 Dec;9(4):301-314
• Study different animal models for reproduce diabetes
type I and their characteristics
• Find the newest gene therapies to treat diabetic
neuropathy and the clinical trials done until now
Objectives
Analyze different kind of information sources like:
• Research papers
• Webs of diabetic associations
• Webs of clinical trials
Choose the best information and data to achieve the previous
objectives
Methods
Animal strains that 
spontaneously 
develop diabetes 
type I
BB rat      
LETL-KDP rat
LEW-iddm rat
Diabetes: 8-16 weeks
Autoantibodies: pancreatic islets and GAD
Hiperglycaemia, insulinopaenia, polyuria, polydipsia,  
ketoacidosis and lymphopenia
Diabetes: 8-16 weeks
Hiperglycaemia, insulinopaenia, polyuria, polydipsia,  
ketoacidosis 
Lymphocyte infiltration in thyroid an kidney
Newest model
Diabetes: 60 days
Low blood levels of insulin, hyperglycaemia, glycosuria and 
ketonuria
Development of the illness similar to humans (without 
peri-insulitis) 
All the clinical features seen in humans
All the clinical features seen in humans
Not lymphopenic
High percentatge of animals with the disease (70-80%)
Not lymphopenic
High percentatge of animals with the disease (70%)
Without  lymphocyte infiltration in other organs different 
to pancreas
They have T-cell lymphopenia: T CD8+ are missing and T CD4+ 
are greatly reduced
They exhibits lymphocyte infiltration in thyroid and kidney
Without autoantibodies against GAD and IA-2
Residual levels of insulin in blood
Table 1. Different animals models for diabetis type I with their characteristics. STZ:streptozotocin, NOD:non-obese diabetic, ROS: reactive oxygen species, GAD:glutamic acid descarboxilasa, IA-2:tyrosine phosphatase ICA512, BB:biobreeding,
LETL long evans Tokushima lean and LEW-iddm: Lewis insulin-dependent diabetes mellitus.
Gene Therapy for Diabetic Neuropathy
• Gen therapy: introduction of genetic material into cells using viral or non-viral vectors that
induces expression or repression of some genes or proteins
• Strategy to treat diabetic neuropathy: express some factors or proteins that show
neuroprotective effects for reverse or avoid damage in patient’s neurons
• Many proteins show neuroprotective effects in vitro and in animals models but only 3
proteins have been used in human clinical trials:
 VEGF (Vascular Endothelial Growth Factor)
 NGF (Nerve Growth Factor)
 GAD 67 (Glutamic Acid Decarboxylase)
• The actual results of these clinical trials (Figure 2), don’t show enough effectiveness .
• New factors are in study and they show promising results in mice model:
 EPO (Erythropoietin)
 SOD + MTs (Super Oxide Dismutase + Metallothionein)
Neuroprotective Factor
VGEF
Phase I/II
(2010)
SB-509
(property of 
Sangamo
BioSciences)
No available
Phase II
(2009)
Naked VEGF
1/2 plasmid
Diabetic
patients with
neuropathy
(n=50)
Reduction in 
pain 
No  changes 
in 
electrophysiol
ogical or 
clinical 
measures
NGF
Phase I
(1998)
Recombinant
human NGF
Diabetic
patients with
neuropathy
(n=250)
Improvement  
in sensory 
component 
examination, 
two 
quantitative 
sensory test 
and the 
patients 
impression     
Phase II
(2000)
Recombinant 
human NGF
HIV patients 
with sensory 
neuropathy 
(n=270)
Improvement 
in daily pain
No different 
in density of 
fibers
Phase III
(2000)
Recombinant
human NGF
Diabetic
patients with
neuropathy
(n=1019)
No difference 
between 
treatment or 
placebo 
group (nerve 
conduction or 
symptoms)
GAD67
Phase I
(ongoing)
HSV vector
GAD67
injected
subcutaneous
No results yet
Conclusions
 Pathways to develop DN are still in study
 Many animal models for diabetes type I exits and everyone of them has its characteristics
and limitations
 The most used for study diabetic complications: mouse injected with STZ (easy and cheap)
 Gene therapy is a new approach to treat DN but only 3 kind of proteins were used in
clinical trails until now (VEGF, NGF, GAD 67) with poor results
 New proteins and factors are in study to future and necessary clinical trials to treat diabetic
neuropathy Figure 2. Representation of the characteristics and results of different clinical trials for treatment of DN. In this order we can see: factor,
phase of clinical trail, treatment and results.
